Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Erkelenz – page 6

1 570 clinical trials in Erkelenz, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Erkelenz at a glance
1 570
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 570 trials in Erkelenz

Open in trial search

Osteomyelitis

Recruiting

Early switch to oral amoxicillin (drug combination) for adults with vertebral osteomyelitis: a randomised non‑inferiority trial

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin
  • Sponsor:University Of Cologne

Study on Golcadomide for Patients with Relapsed or Refractory Large B-Cell Lymphoma in the Brain

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Golcadomide
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study on the Long-Term Safety of Belimumab for Adults with Systemic Sclerosis-Related Lung Disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Comparing 18F-FDG and 68Ga-FAPI-46 for PET Scans in Patients with Hormone-Positive Breast Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:68Ga-FAPI-46
  • Sponsor:University Hospital Maastricht

Study on Bortezomib and Drug Combination for Children with High-Risk Relapsed Acute Lymphoblastic Leukemia (ALL)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Bortezomib
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Study on the Effects of Baricitinib and Drug Combination for Adults with Severe Community-Acquired Pneumonia, Severe Influenza, or Severe and Moderate COVID-19

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amoxicillin Sodium
  • Sponsor:Universitair Medisch Centrum Utrecht

Study of NTLA-2001 for Patients with Transthyretin Amyloidosis and Heart Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Intellia Therapeutics Inc.

Prostate cancer

Recruiting

Study on Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan for Adults with Prostate Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lutetium (177LU) vipivotide tetraxetan
  • Sponsor:Novartis Pharma AG

Study Comparing Clindamycin to Rifampicin and Drug Combination for Patients with Prosthetic Joint Infection

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Clindamycin
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:AstraZeneca AB

Breast cancer

Recruiting

Study of Tersolisib and a drug combination for adults with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Eli Lilly & Co.

Efficacy and Safety of Three Different Doses of Pirtobrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Previously Received BTK Inhibitor Treatment

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Eli Lilly & Co.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Erkelenz

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on triple-negative breast cancer evaluating the effectiveness of combining immunotherapy with traditional chemotherapy treatments. Studies aim to improve patient outcomes through personalized therapeutic approaches.

  • Triple-Negative Breast Cancer Treatment
  • Immunotherapy Integration
  • Event-Free Survival Assessment

Research explores novel combination therapies to enhance treatment efficacy.

02 Hormone Receptor Research

Studies examining personalized treatment strategies for HR+/HER2- breast cancer patients, comparing endocrine therapy combinations with standard chemotherapy approaches. Focus on long-term survival outcomes.

  • Endocrine Therapy Enhancement
  • Disease-Free Survival Analysis
  • Personalized Treatment Protocols

Investigation of targeted therapies to improve treatment effectiveness.

03 Advanced Treatment Studies

Research evaluating novel therapeutic approaches for HER2-negative breast cancer patients, particularly those at high risk of relapse after standard treatments. Focus on comparing innovative targeted therapies with conventional approaches.

  • High-Risk Patient Treatment
  • Relapse Prevention Strategies
  • Comparative Treatment Efficacy

Development of targeted solutions for challenging breast cancer cases.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.